1. Home
  2. SCLX vs SFWL Comparison

SCLX vs SFWL Comparison

Compare SCLX & SFWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • SFWL
  • Stock Information
  • Founded
  • SCLX 2011
  • SFWL 2001
  • Country
  • SCLX United States
  • SFWL China
  • Employees
  • SCLX N/A
  • SFWL N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • SFWL Trucking Freight/Courier Services
  • Sector
  • SCLX Health Care
  • SFWL Industrials
  • Exchange
  • SCLX Nasdaq
  • SFWL Nasdaq
  • Market Cap
  • SCLX 81.7M
  • SFWL 91.6M
  • IPO Year
  • SCLX N/A
  • SFWL 2023
  • Fundamental
  • Price
  • SCLX $0.48
  • SFWL $1.06
  • Analyst Decision
  • SCLX Strong Buy
  • SFWL
  • Analyst Count
  • SCLX 3
  • SFWL 0
  • Target Price
  • SCLX $11.33
  • SFWL N/A
  • AVG Volume (30 Days)
  • SCLX 184.3K
  • SFWL 55.1K
  • Earning Date
  • SCLX 12-24-2024
  • SFWL 09-04-2024
  • Dividend Yield
  • SCLX N/A
  • SFWL N/A
  • EPS Growth
  • SCLX N/A
  • SFWL N/A
  • EPS
  • SCLX N/A
  • SFWL 0.11
  • Revenue
  • SCLX $50,833,000.00
  • SFWL $446,281,000.00
  • Revenue This Year
  • SCLX $32.77
  • SFWL N/A
  • Revenue Next Year
  • SCLX $50.71
  • SFWL N/A
  • P/E Ratio
  • SCLX N/A
  • SFWL $9.93
  • Revenue Growth
  • SCLX 9.41
  • SFWL 14.80
  • 52 Week Low
  • SCLX $0.46
  • SFWL $0.81
  • 52 Week High
  • SCLX $2.63
  • SFWL $5.53
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 33.34
  • SFWL 44.67
  • Support Level
  • SCLX $0.48
  • SFWL $1.02
  • Resistance Level
  • SCLX $0.54
  • SFWL $1.24
  • Average True Range (ATR)
  • SCLX 0.06
  • SFWL 0.06
  • MACD
  • SCLX -0.00
  • SFWL -0.00
  • Stochastic Oscillator
  • SCLX 4.53
  • SFWL 52.00

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About SFWL Shengfeng Development Limited

Shengfeng Development Ltd is a holding company. The company offers contract logistics services comprising planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The integrated logistics solution services of the company are comprised of three segments: B2B freight transportation; cloud storage; and value-added services.

Share on Social Networks: